Australia will spend $50 million building the world’s first long-term artificial heart,after the original prototype was built with pieces bought from Bunnings.
Investors have punished the company’s share price for the second day in a row – despite it booking revenue of $12.3 billion for the half-year to December 31.
Shares in the blood plasma treatments maker were trading nearly 5 per cent lower following the results.
Australia’s underinvestment in research is becoming a national security issue,some university heads argue,ahead of a landmark review and the AUKUS deal.
After rubbing shoulders in Singapore with Prince William,Sea Forest founder Sam Elsom is eager for the Albanese government to back his plan to help save the planet.
The winners of the environmental awards,established by the heir to the British throne,each received $1.91 million in prize money after being announced in Singapore.
Muscle-mass preservation is becoming a hot new area in obesity medicine.
From health to fast food,investors are starting to question which companies will be slimmed thanks to weight-loss drugs.
CSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.
Shareholders have grilled the biotech giant about its long-term strategy as the stock sits close to 10 per cent lower for the year.
The ASX heavyweight and the nation’s largest healthcare company is looking to make its operations more efficient to counter inflation and currency woes.